A study into the process of retinal cell death could hold the key to stopping a variety of eye diseases that cause blindness, according to a report from a team of researchers from the Yale School of Medicine reported in the journal Investigative Ophthalmology & Visual Science.
A study into the process of retinal cell death could hold the key to stopping a variety of eye diseases that cause blindness, according to a report from a team of researchers from the Yale School of Medicine reported in the journal Investigative Ophthalmology & Visual Science.
The breakdown of retinal cells known as photoreceptors is common to several diseases that cause blindness. In the diseases the researchers studied the photoreceptors were dying from a variety of causes, but common to all cases was the activation of a family of molecules called CREB1/ATF1. The team then attempted to determine if the molecules were contributing to the cell death or were being activated in an attempt to prolong cell life.
Studying retinas treated with a drug known to preserve photoreceptors, the researchers found much higher levels of CREB1/ATF1, suggesting the molecules act as part of the protective mechanism.
"Not only did we find that the drug activated the novel CREB1/ATF1 photoreceptor pathway, but we found that this activation was caused by stress," said Caroline Zeiss, associate professor of comparative medicine and ophthalmology at Yale School of Medicine, USA, in a statement. "This suggests that CREB/ATF1 may be an innate protective response that could be used to achieve broad spectrum preservation of the retina."
AAO 2023: Company updates from Centricity Vision CEO Rob Thornhill
November 28th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.
AAO 2023: Marco A. Zarbin, MD, PhD, provides analysis of the YOSEMITE and RHINE clinical trials
November 24th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials